Corgi BE 2X Daily ETF (BEC)

$BE $BEC $BEX SPRTS = 200+197+188+185 +180<---B🎯

$BE $BEC $BEX BITCOIN RESIST =64205+64663+64752+66333+67176+68942 +69885(100DMA)

$BE $BEC $BEX SPRTS= 176.36 (200dma) *must hold or sell +164+153 +146+140 RSIST= 194+199(VWAP) +206+215 +230(100DMA)

$BE $BEX $BEC SPRT= 195.65 gap⤵️ + 174 (200dma)🎯 RSIST= 205.15 +208.46 ( 5-day resistance clearly seen on the chart above that it could be a Breakout +220 +225+229(100dma)+232(9dma)+240 +253+270

$BE $BEC <-- watching to a load a position of this

$BEC $BE - BEC is the new 2X long ETF for BE. Chart linked below shows lower trendline still intact. Feeling https://finviz.com/stock?t=BE&ty=c&p=d&b=1

$BE $BEC <-- NEW 2X ETF TECHNICALL: looks like it's still in a downtrend supports the watch are =234.00 + 230.00 (T-LINE) 1ST Buy🎯+223(100dma) 2nd BUY 🎯 I won't mention any more support still breaks that which I don't think it will RESIST= 248+250+257+🚀 to 271.00

$TBIO $BEC Telesis Bio and Beckman Coulter team to enable 'breakthrough' discoveries A new partnership between Telesis Bio (TBIO )and Beckman Coulter Life Sciences (BEC) will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The collaboration integrates Telesis Bio's Gibson SOLA Enzymatic Synthesis technology with the new Biomek Echo One System from Beckman Coulter Life Sciences. It also delivers an open solution to the market, allowing the incorporation of constructs from other providers compatible with Gibson SOLA, further expanding the technology's flexibility to synthesize unique or challenging biology. .."This partnership with Telesis Bio delivers on our promise to be a trusted and preferred laboratory partner, to more quickly and accurately enable breakthrough research discoveries," said Ewan Grant, Senior Director of the Biotech Workflow Solutions Business Unit at Beckman Coulter Life Sciences. "This innovation brings exciting new possibilities to DNA and mRNA synthesis workflows, unleashing the benefits of our new Biomek Echo One System including seamlessly executing library preparation steps such as extraction, fragmentation, ligation, normalization and pooling along with requisite actions such as centrifugation, shaking and thermal incubation in one automated method."

$TTOO $DHR $BEC

$TTOO $DHR $BEC